Provisional determination for new COVID treatment

green light new law approval
Sabizabulin’s sponsor can now seek provisional registration for the treatment of COVID-19, says the TGA The Therapeutic Goods Administration has announced that it has granted a provisional determination to Adjutor Healthcare Pty Ltd for a new orally-administered medicine, sabizabulin, for the treatment of COVID-19. “The determination means that Adjutor Healthcare is now able to apply

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous More support for people with asthma
Next Much-needed clarity on rego conditions